Geron 5th Patient injected

The Stanford University School of Medicine and Santa Clara Valley Medical treated the fifth patient in the Geron Corp. sponsored trial of a human embryonic-stem-cell-derived treatment for spinal cord injury on Nov. 16th.
Humans may need longer than a year to show results. It was shown that primates require more time than rats to recuperate.
Phase I results for GRN1005, Geron found the peptide/paclitaxel conjugate to be generally well tolerated. Since paclitaxel itself is an approved product, this is good news. Geron plans to initate two Phase II clinical trials for GRN1005 soon [December 2011] with data to become available in the first half of 2013. With good results it will most likely be fast tracked.


ACTC is in two Phase 1/2 trials, which injects embryonic stem cells into the eye,  one for Stargardt's Macular Dystrophy and Dry Age Related Macular Degeneration. Interesting news, patients want their second eye injected. That's a very strong indication that they are experiencing improvement. The studies are notable because Catholic nuns are among the patients. That is wild.

I'm long Geron and ACTC.

Good luck is this rigged casino,

Ruff Week for Longs

The high for the week was $2.32 on Nov. 14th the new low for the year was $1.50 on Nov. 18th.  The five day avg, volume was 3,607,10 shares, ten day avg. was 2,314,856, three month avg. volume was 1,597,230.  We will go lower without positive news. Geron decision to continue pursuing the oncology programs will make or break them. By the end of 2012 if the four Phase II trial results are less then outstanding, I will sell most of my shares. Right now any move over $2.00 will sell a few shares and covered calls.

Partners are still needed.

Good luck in this rigged casino,

Setback for the whole stem cell research industry

Joseph Pantginis an analyst with Roth Capital Partners said it would have taken five to ten years before Geron's lead stem cell product reached the market.

This was a classic business calculation, you have two blockbuster programs but only enough money for one, so you choose the one that is further along.

Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.

The share price is worrying me. It could go below a dollar. Only good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding I will sell most of my shares. For now any move over $2 I will sell some shares and sell a few covered calls.

I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company.

Good luck in this rigged casino,

Geron now totally focused on Imetelstat

Imetelstat could be part initial therapy and maintence thrapy in 90% of all cancers.  Whether as a single agent or in combination with other drugs, it looks like a telomerase inhibitor can have a role in cancer treatment. The Phase II trial will answer that question at the end of 2012. If so, Imetelstat may be the first and only drug that has the benefit that hits CSCs. It could be the blockbuster of all time in cancer. That's why GERN decided it could not afford to expend its limited resources on ESCs. It's still very dispointing but with limited funds a choice had to be made.

Good luck in this rigged casino,

Chip buys 80,000 shares Geron

That's  the rumor on Yahoo's Message Broad. Chip will do what it takes to made this company survive. Over 9 million shares traded down 20%. I bought at $1.85 and $1.80 pre-market, that was a mistake. I think we'll go back to $2+ after the new year starts.

Again, I'm very disappointed by the halting of the stem cell research. It's very sad.

Geron plans to partner all stem cell program. They will be lucky to get pennies on the dollar.

Good luck in this rigged casino,

Geron halting stem cell research

Geron to focus on its novel cancer programs.

This is bad short term, good long term. Geron saw the writing on the wall, running out of money fast. They now may have time to get a blockbuster product to market before they have to do a 2nd offering at under $2.00.

Geron plans to partner all stem cell programs, meaning the partner will have to foot the total bill.

The GRN1005  is entering two Phase 2 trials this year data from these trials should be out before the end of the 2nd quarter of 2013.

The four Phase 2 clinical oncology studies will have data by the end of 2012. If any are good Geron will find a partner.

Conference call Nov. 15 at 9AM I will be listening.

I am very disappointed by the halting of the stem cell research. I still believe in the science. Geron needs a very very rich partner to fund this.

We will take a big hit tomorrow. I will buy a few shares around $1.75 or lower.

Good luck in this rigged casino,

Unlocking Amazing Potential of Stem Cell Therapy

NEW YORK, NY, Nov 14, 2011 (MARKETWIRE via COMTEX) -- The case for increased stem cell funding is growing by the day as the potentially lifesaving effects of regenerative medicine continue to be revealed. Scientists argue that stem cells are the future of healthcare, and that regenerative medicine is one of the most misunderstood fields in biotechnology. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on Advanced Cell Technology, Inc. (ACTC, Trade ) and Geron Corporation (GERN, Trade ). Ground breaking studies out of Japan earlier this month showed the vast reach of stem cell medicine. A research team at Japan's RIKEN Center for Developmental Biology successfully used stem cells to synthesize a fully functioning organ entirely from scratch. The team somehow managed to take mouse stem cells and transformed them into a working pituitary gland, which is a small organ that lives at the base of your brain and produces hormones that help you grow.
The Bedford Report releases stock research on the Biotechnology Insurance Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Headlines regarding the funding (or lack thereof) for embryonic stem cell research have a habit of moving all stem cell related stocks, even those not involved in the controversial sector. Very few publicly traded companies are actually engaged in embryonic stem cell research.
Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The company recently reported a loss from operations of $6.9 million for the third quarter ended September 30, 2011. This compares with a loss from operations of $5.4 million reported in the third quarter of 2010.
Geron Corporation is developing cell therapies from differentiated human embryonic stem cellswith the first product in a Phase 1 clinical trial for spinal cord injury. For the third quarter of 2011, the company reported a net loss of $19.5 million, or $0.16 per share, compared to $18.3 million, or $0.19 per share, for the comparable 2010 period
Let's see if this will move the share price. I'm long big time GERN and ACTC.

Good luck in this rigged casino,